Amgen(AMGN) To Buy Biovex For Cancer Vaccine Technology
Biologics for Treatment of Cancer and Prevention of Infectious Disease Amgen(AMGN) and Biovex said today that both Boards approved the sale of privately held Biovex for $425M with milestone payments as much as $525M. The Biovex lead product OncoVex, an oncolytic vaccine, is in a Phase III...
Life Science News Update:$700M in Fed Research Center at NIH; AD Diagnosis
Will the GOP cut the NIH budget? Turf battles at the Institutes to follow. Who knew there were only two breakthroughs in mental health drugs: Thorazine and Lithium? Federal Research Center Will Help Develop Medicines - NYTimes.com Most experts believe the PET Imaging procedure can be helpful....
Biotech Movers du jour: Clinical Data (CLDA) and Genoptix (GXDX)
Novartis (NVS) acquires Genoptix(GXDX $24.84) for $470M-Stock is up 25% The biotech diagnostics and tools sector was ignited today with acquisition of Genoptix, a provider of laboratory services for hematology and oncology. Genoptix put itself up for sale in December and is an emerging niche...
Venture Capital Recovers, Biotechnology Gets $3.7B in 2010
Venture Capitalists invested $21.8B in 2010 an increase of 19% over the prior year. Biotechnology was up 3% over the prior year to $3.7B with 460 deals. Software was the leader rising 20% to $4B. Medical Device was flat year over year with $2.3B invested. ANNUAL VENTURE INVESTMENT INCREASES FOR...
Rayno Life Science Portfolio 2011:Time to Raise a Little Cash
Time for Caution-Raise Cash After the Big Q4 2010 Run Here are some guidelines for the Rayno Life Science Portfolio: Smaller cap high beta biopharma stocks are at risk. No new buys. Our mid-cap index is still weak. Tools and diagnostics will be less volatile. ABAX, GPRO, ILMN. Raise cash or...